FSG67
CAS No. 1158383-34-6
FSG67( —— )
Catalog No. M35491 CAS No. 1158383-34-6
FSG67 is an inhibitor of glycerol 3-phosphate acyltransferase (IC 50 =24 μM) .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 2MG | 140 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 376 | In Stock |
|
| 25MG | 748 | In Stock |
|
| 50MG | 1097 | In Stock |
|
| 100MG | 1655 | In Stock |
|
| 200MG | 2260 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFSG67
-
NoteResearch use only, not for human use.
-
Brief DescriptionFSG67 is an inhibitor of glycerol 3-phosphate acyltransferase (IC 50 =24 μM) .
-
DescriptionFSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC50 of 24 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1158383-34-6
-
Formula Weight327.44
-
Molecular FormulaC16H25NO4S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (305.40 mM; Ultrasonic )
-
SMILESCCCCCCCCCS(=O)(=O)Nc1ccccc1C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Myricetin-3-robinobi...
Myricetin-3-O-robinoside is a flavonoid isolated from cassava flowers by chromatographic techniques. Its structure consists of a myricetin backbone to which a robinose moiety is attached at the third position.
-
Adrenocorticotropic ...
Adrenocorticotropic Hormone (ACTH) (1-39), rat is a potent melanocortin 2 (MC2) receptor agonist.Peptide fragments of ACTH (1-39) were formed during in vitro incubation of the peptide with membrane preparations. ACTH (1-39) were isolated by high pressure liquid chromatography, and peptide fragments of ACTH (1-39) characterized by determination of amino acid composition and NH2- terminal residue.
-
Vazegepant HCl
Vazegepant is the first intranasal gepant for the acute treatment of migraine and has announced a positive phase II/III study.
Cart
sales@molnova.com